Markets

Why Amgen Stock Perked Up Last Month

What happened

Biotech heavyweight Amgen (NASDAQ: AMGN) saw its shares gain a healthy 12.2% over the course of August, according to data from S&P Global Market Intelligence. What triggered this double-digit move higher?

On Aug. 9, the U.S. District Court for the District of New Jersey upheld the two patents protecting the anti-inflammatory medicine Enbrel from biosimilar competition until 2029. Novartis' (NYSE: NVS) Sandoz division is attempting to invalidate the patents in order to launch its Enbrel biosimilar, known as Erelzi. Erelzi was approved three years ago by the Food and Drug Administration (FDA), but it has yet to launch because it infringes on those two key patents.  

A researcher in a lab coat pointing to a section of DNA.

Image Source: Getty Images.

So what

Enbrel has long been Amgen's best-selling medicine. So it's not surprising that investors cheered this verdict last month. Now, Novartis does reportedly plan on challenging the court's ruling, but as things stand now, Amgen appears to have the upper hand in this long-running legal battle. That's key because it means Amgen's biggest cash cow should remain a key contributor to the biotech's top line for years to come.   

Now what

In addition to this major legal win, Amgen also acquired Celgene's anti-inflammatory medicine Otezla for a whopping $13.4 billion last month, and it recently reported encouraging trial results for the novel anti-cancer treatment AMG 510 as well. With all these positive developments, Amgen has significantly improved its long-term outlook over the past few weeks. In fact, the biotech is expected to post a noteworthy 9.9% increase in annual sales next year, thanks largely to this Otezla acquisition. That being the case, this blue-chip biotech stock arguably comes across as an outstanding buy right now.  

10 stocks we like better than Amgen
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has quadrupled the market.*

David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Amgen wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

 

*Stock Advisor returns as of June 1, 2019

 

George Budwell has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Celgene. The Motley Fool recommends Amgen. The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

AMGN NVS

Latest Markets Videos

    The Motley Fool

    Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.

    Learn More